Merck & Co to repurpose failed obesity drug for NASHMerck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson Share XMerck & Co to repurpose failed obesity drug for NASHhttps://pharmaphorum.com/news/merck-co-to-repurpose-failed-obesity-drug-for-nash/
MiNA’s gene-activating tech wins an AstraZeneca allianceUK biotech MiNA Therapeutics’ RNA-based gene-activating technology has caught the eye of big pharma AstraZeneca. AZ has teamed Share XMiNA’s gene-activating tech wins an AstraZeneca alliancehttps://pharmaphorum.com/news/minas-gene-activating-tech-wins-an-astrazeneca-alliance/
Novo’s new oral GLP-1 Rybelsus still has obstacles to overcomeThe FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the Share XNovo’s new oral GLP-1 Rybelsus still has obstacles to overcomehttps://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/
Vertex looks beyond cystic fibrosis with $950m Semma buyVertex Pharma is all-but synonymous with cystic fibrosis (CF) treatment but wants to diversify into new areas, including Share XVertex looks beyond cystic fibrosis with $950m Semma buyhttps://pharmaphorum.com/news/vertex-looks-beyond-cystic-fibrosis-with-950m-semma-buy/
Pfizer, Novo invest in Swedish patient stratification startupFunds will go towards development of AMRA’s body composition profiling tool AMRA Profiler. Share XPfizer, Novo invest in Swedish patient stratification startuphttps://pharmaphorum.com/news/pfizer-novo-invest-swedish-patient-stratification-startup/